Liftstream is an executive search recruitment company in the life sciences sector
Voyager Therapeutics, a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Jane Pritchett Henderson as senior vice president and chief financial officer effective January 1, 2017. Ms. Henderson brings more than 28 years of life sciences industry and banking experience and leadership to her new role.
AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has made three senior appointments. Joining the firm’s leadership team are Kim Warren, Head of Operations, Chris Mason, Chief Science Officer, and Deanna Petersen, Chief Business Officer.
Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance.
Scott Morrison, a retired Ernst & Young Partner, was appointed to the board of directors at Audentes Therapeutics and Global Blood Therapeutics.Watch Full Movie Online Streaming Online and Download
Just days after setting the terms for its pending IPO, Dimension Therapeutics, Inc., a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, announced the election of Alan B. Colowick, M.D., M.P.H., Executive Vice President of Celgene Corporation, to Dimension’s Board of Directors. Dr. Colowick brings strong operational expertise and more than 15 years of experience in biopharmaceutical development. His election to the company’s Board is effective immediately.
Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. Morris, former CEO of Syndax Pharmaceuticals. Dimension also announced that Donald J. Hayden, Jr., is leaving his position as a member of the Company’s Board of Directors.
Third Rock Ventures portfolio company, Voyager Therapeutics, a gene therapy player in the field of CNS based out of Cambridge, Mass. have appointed Michael Higgins to the Board of Directors. Mr. Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation, with which Voyager Therapeutics now has a partnership, from 1997 through 2003 in a variety of leadership roles, including vice president of corporate finance and vice president of business development. While at Genzyme, he was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.